Epic’s Genomics Module Moves Pharmacogenomics From Static Reports to Bedside Decisions
Pharmacogenomic testing can identify patients whose drug response is altered by inherited variation, but the result only changes care when it reaches the prescriber in a usable form. A 2025 tutorial in Clinical Pharmacology & Therapeutics lays out how University of Florida Health built that bridge with Epic’s Genomics module, an add-on to the core electronic health record designed to store structured genomic data and trigger clinical decision support. The article is not a trial of efficacy in the conventional sense; it is a practical implementation guide. Even so, its clinical importance is immediate, because the value of pharmacogenomics collapses if the result sits in a lab report that never reaches the medication order screen.
The deployment began in early 2022 at University of Florida Health, where the Precision Medicine Program integrated the module into routine care. The tutorial describes the steps taken to make genomic information actionable inside the EHR, with special attention to the mechanics of pharmacogenomics clinical decision support. In practice, that means the system is designed not just to store a genotype, but to surface the information when a clinician is ordering a drug with a known gene-drug association. For bedside prescribers, the distinction matters because most medication decisions happen under time pressure, and a passive report rarely changes behavior.
One sentence captures the operational challenge: genomic data must be structured before it can be useful.
The Epic module exists to solve that problem by turning pharmacogenomic results into discrete data elements that the health record can recognize and act on. That structure supports alerts, reminders, and other CDS tools that are embedded into workflow rather than bolted onto it. The tutorial frames this as a necessary condition for successful implementation, not an optional technical upgrade. Without structured data, even a well-validated result can disappear into scanned documents, fragmented notes, or external laboratory portals that do little to guide prescribing at the point of care.
Building CDS Around Real Prescribing Workflow
The article emphasizes that implementation is more than software installation. A successful rollout requires coordination between precision medicine teams, information technology staff, clinicians, and the workflows that govern medication ordering and result reporting. Epic’s Genomics module was used as the platform for that coordination at University of Florida Health, with the Precision Medicine Program leading the deployment effort. The tutorial identifies key factors for success, which places the focus on governance, clinical alignment, and the practical translation of genomic evidence into everyday prescribing decisions.
That framing reflects an important pharmacologic reality: the clinical action tied to a pharmacogenomic result depends on the drug, the gene, and the decision being made at the moment of prescribing. A CDS system has to deliver the right information at the right time, or the result loses much of its value. In that sense, the module is less a repository than a decision infrastructure. When it works, it can help clinicians avoid adverse drug reactions, select alternative therapies, or adjust dosing before harm occurs. When it fails, testing may still be scientifically correct but clinically inert.
The tutorial positions CDS as the central mechanism for translating pharmacogenomic knowledge into practice. That is biologically plausible and operationally sound. Genotype influences drug metabolism, transport, or target response; the EHR then needs to connect that biology to the medication list. In a conventional workflow, the barrier is not a lack of evidence but a lack of integration. Epic’s module is designed to reduce that gap by combining storage of genomic data with rules-based clinical prompts built for PGx use cases.
Why Structured Genomic Data Matters at the Point of Care
For clinicians, the value of the module lies in visibility. Pharmacogenomic information is only helpful if it is available at the moment a drug is prescribed, renewed, or reconciled. Structured storage in the EHR makes that possible across encounters and specialties, which is especially important when patients receive care from multiple teams. The tutorial makes clear that a successful implementation has to work inside routine clinical operations rather than depend on individual memory or manual lookup.
The report also shows how pharmacogenomics is moving from a specialty testing service toward a more durable component of mainstream care. That shift depends on infrastructure. A health system can generate high-quality genomic data and still fail to affect outcomes if the information cannot be interpreted quickly by frontline clinicians. CDS changes that equation by embedding recommendations into the existing electronic workflow. In practical terms, the EHR becomes the delivery mechanism for evidence-based prescribing guidance rather than a passive archive.
Another punchy reality follows from that design: if the alert is poorly timed or hard to act on, the whole system loses force.
This is why implementation strategy matters as much as assay selection. The article’s focus on “key factors for a successful implementation” signals that the University of Florida Health experience involved more than turning on a software module. It required thoughtful integration of genomic results, clinical content, and user-facing tools. For institutions considering similar programs, the tutorial functions as a blueprint for how to move from pilot pharmacogenomics to routine operational use.
The Bedside Stakes of Pharmacogenomics Integration
The clinical stakes are straightforward. Drug response varies across patients, and inherited variation can meaningfully alter exposure, efficacy, or toxicity. A CDS-enabled genomics module aims to reduce preventable mismatch between the patient and the medication. That matters in any setting where a common prescription can become a poor choice once genotype is known. The tutorial does not present outcome data for a specific drug or a measured reduction in adverse events, and it should not be read as such. Its contribution is implementation knowledge: how to make pharmacogenomic information visible, actionable, and persistent inside the health record.
That distinction is important for health systems weighing whether to invest in genomics infrastructure. Evidence alone does not change prescribing patterns. Systems do. The University of Florida Health experience, as summarized in this tutorial, suggests that Epic’s Genomics module can supply the technical framework needed for that system-level change. The goal is not simply to collect more genetic information, but to make sure the right clinical warning, recommendation, or dosing cue appears when it can still influence treatment.
For precision medicine programs, the message is practical. Successful pharmacogenomics implementation depends on structured data, workflow fit, institutional coordination, and CDS that clinicians can use without leaving the order screen. The tutorial offers a real-world account of how one academic health system approached that task in early 2022, and it leaves open the questions that matter next: how broadly such systems can be adopted, how well they generalize across institutions, and how consistently they improve prescribing once embedded in routine care.